Other News To Note
Friday, February 3, 2012
Compugen Ltd., of Tel Aviv, Israel, reported findings on the potential of CGEN-15001T, a membrane protein, as a therapeutic target for multiple cancers using monoclonal antibody (mAb) therapy. The results indicated that CGEN-15001T is expressed on numerous types of cancer, including carcinomas, sarcomas, melanoma and hematological cancers, as well as on immune cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.